Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial

Dendreon Corporation (Nasdaq: DNDN) announced that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial designed to

More: continued here

Filed under: Prostate on October 13th, 2008